| scholarly article | Q13442814 |
| P2093 | author name string | Allison R Jilbert | |
| Andrew Vaillant | |||
| Faseeha Noordeen | |||
| P2860 | cites work | 1H NMR study on equilibrium between parallel G-quartet structures | Q79410192 |
| Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry | Q27490785 | ||
| Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate | Q29618203 | ||
| Structural basis for membrane fusion by enveloped viruses | Q33637921 | ||
| Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers | Q33652265 | ||
| Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. | Q33698569 | ||
| Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue | Q33702993 | ||
| Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. | Q33755065 | ||
| Immune effects and mechanisms of action of CpG motifs | Q34088619 | ||
| Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides | Q34509751 | ||
| Evidence for intramolecularly folded i-DNA structures in biologically relevant CCC-repeat sequences | Q34892950 | ||
| Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection | Q35166065 | ||
| Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles | Q35844533 | ||
| Duck hepatitis B virus: an invaluable model system for HBV infection. | Q35941634 | ||
| Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo | Q36804032 | ||
| Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection | Q37477905 | ||
| Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. | Q38306474 | ||
| Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells | Q38322849 | ||
| Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells | Q38331386 | ||
| Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation | Q40298802 | ||
| Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs | Q41500655 | ||
| Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. | Q42277109 | ||
| The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines. | Q42910291 | ||
| Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection. | Q44147445 | ||
| DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection | Q45395747 | ||
| DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner | Q45417490 | ||
| Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection | Q45419954 | ||
| Studying host immune responses against duck hepatitis B virus infection. | Q45695227 | ||
| Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses | Q45738931 | ||
| Characterization of age- and dose-related outcomes of duck hepatitis B virus infection. | Q45755958 | ||
| Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks | Q45765889 | ||
| Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. | Q46214167 | ||
| Spectroscopic evidence for the formation of four-stranded solution structure of oligodeoxycytidine phosphorothioate | Q73106793 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| hepatitis B | Q6853 | ||
| P304 | page(s) | 5299-5306 | |
| P577 | publication date | 2013-08-12 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo | |
| P478 | volume | 57 |
| Q46263692 | Activity of nucleic acid polymers in rodent models of HBV infection |
| Q35245221 | Animal models and the molecular biology of hepadnavirus infection |
| Q90136072 | Chronic hepatitis delta: A state-of-the-art review and new therapies |
| Q59353537 | Current and Future Management of Chronic Hepatitis D |
| Q52764230 | Drugs in Development for Hepatitis B. |
| Q26782127 | Hepatitis B virus infection: An insight into infection outcomes and recent treatment options |
| Q39414876 | Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen |
| Q33821878 | Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes |
| Q42209643 | Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy |
| Q45323707 | Nucleic acid polymers are active against Hepatitis Delta Virus infection in vitro |
| Q42277109 | Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. |
| Q26741235 | Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection |
| Q40302798 | Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells |
| Q42207445 | Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps. |
| Q41588940 | Recent advances in managing hepatitis D |
| Q36039553 | Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection |
| Q35839139 | Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection |
| Q26795919 | Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection |
| Q40255481 | Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: evidence from a duck model of hepatitis B virus |
| Q38794446 | Treatment of hepatitis B virus: an update |
Search more.